PE20040935A1 - Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina - Google Patents
Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicinaInfo
- Publication number
- PE20040935A1 PE20040935A1 PE2004000034A PE2004000034A PE20040935A1 PE 20040935 A1 PE20040935 A1 PE 20040935A1 PE 2004000034 A PE2004000034 A PE 2004000034A PE 2004000034 A PE2004000034 A PE 2004000034A PE 20040935 A1 PE20040935 A1 PE 20040935A1
- Authority
- PE
- Peru
- Prior art keywords
- quinazoline
- trifluoromethyl
- alkyl
- ilamine
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
SE REFIERE A ANALOGOS DE 2-QUINAZOLINA SUSTITUIDA-4-ILAMINA DE FORMULA I, O UNA FORMA FARMACEUTICAMENTE ACEPTABLE DE ESTOS, DONDE X, V, W, Y y Z SON N o CR1, CON LA CONDICION DE QUE AL MENOS UNO DE V y X SEA N; R1 ES H, HALOGENO, HIDROXIDO, CIANO, ENTRE OTROS; R ES OR7 o N(R3)(R4); R7 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ALCANOIL C2-C8, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; O R3 Y R4 JUNTOS FORMAN UN ANILLO HETEROCICLICO DE 4-10 MIEMBROS; R5 o R6 SON H, ALQUILO C1-C8, O CADA UNO JUNTO CON R3, R4 o R7 FORMAN UN ANILLO HETEROCICLICO DE 4-10 MIEMBROS; n ES 1, 2 o 3; Ar1 Y Ar2 SON GRUPOS ARILOS DE 6-10 MIEMBROS o GRUPOS HETEROCICLICOS DE 5-10 MIEMBROS. SON COMPUESTOS PREFERIDOS: [2-ISOPROPOXIMETIL-7-(3-TRIFLUOROMETIL-PIRIDINA-2-IL)-QUINAZOLINA-4-IL]-(4-TRIFLUOROMETIL-FENIL)-AMINA; 2-[4-(4-TRIFLUOROMETIL-FENILAMINA)-7-(3-TRIFLUOROMETIL-PIRIDINA-2-IL)-QUINAZOLINA-2-IL]-ETANOL; [2-(2-METOXI-ETIL)-7-(3-TRIFLUOROMETIL-PIRIDINA-2-IL)-QUINAZOLINA-4-IL]-(4-TRIFLUOROMETIL-FENIL)-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE CAPSAICINA REDUCIENDO LA CONDUCTANCIA DEL CALCIO DE DICHO RECEPTOR
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43313902P | 2002-12-13 | 2002-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040935A1 true PE20040935A1 (es) | 2005-01-01 |
Family
ID=32595121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000034A PE20040935A1 (es) | 2002-12-13 | 2004-01-05 | Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina |
Country Status (13)
Country | Link |
---|---|
US (2) | US20040156869A1 (es) |
EP (2) | EP1569926A1 (es) |
JP (2) | JP2006515846A (es) |
KR (1) | KR20050084292A (es) |
CN (1) | CN1726205A (es) |
AR (1) | AR042461A1 (es) |
AU (2) | AU2003296984A1 (es) |
BR (1) | BR0317168A (es) |
CA (2) | CA2509239A1 (es) |
MX (1) | MXPA05006123A (es) |
PE (1) | PE20040935A1 (es) |
TW (1) | TW200418480A (es) |
WO (2) | WO2004055004A1 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
CA2509616A1 (en) * | 2002-12-13 | 2004-07-01 | Neurogen Corporation | Combination therapy for the treatment of pain |
MXPA05006123A (es) * | 2002-12-13 | 2005-09-30 | Neurogen Corp | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. |
ATE365167T1 (de) * | 2003-07-10 | 2007-07-15 | Neurogen Corp | Aryl-substituierte benzo(d)isothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren |
TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
EP1678173A2 (en) * | 2003-09-09 | 2006-07-12 | Neurogen Corporation | 4-heterobicyclylamino-substituted quinazolines and analogues thereof as capsaicin-antagonists |
DK2392564T3 (da) | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
EP1713807A1 (en) * | 2004-01-23 | 2006-10-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
AU2005221614A1 (en) * | 2004-03-04 | 2005-09-22 | Neurogen Corporation | Arylalkylamino-substituted quinazoline analogues |
EP1732560A4 (en) * | 2004-04-08 | 2010-08-18 | Neurogen Corp | SUBSTITUTED CINNOLINE-4-YLAMINE |
JP2008508190A (ja) * | 2004-07-19 | 2008-03-21 | ノボ ノルディスク アクティーゼルスカブ | 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害 |
TW200621251A (en) * | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
AU2006208042A1 (en) * | 2005-01-25 | 2006-08-03 | Neurogen Corporation | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues |
KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
US8232278B2 (en) | 2005-06-24 | 2012-07-31 | Gilead Sciences, Inc. | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C |
CN101243081A (zh) * | 2005-07-21 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物 |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
CN101360746B (zh) * | 2005-11-22 | 2013-12-11 | 库多斯药物有限公司 | 作为mTOR抑制剂的吡啶并-、吡唑并-和嘧啶并-嘧啶衍生物 |
EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
KR20080080395A (ko) * | 2005-12-21 | 2008-09-03 | 아보트 러보러터리즈 | 항바이러스 화합물 |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
RU2467007C2 (ru) | 2005-12-21 | 2012-11-20 | Эбботт Лэборетриз | Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv |
US20080058312A1 (en) * | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
US20080153845A1 (en) * | 2006-10-27 | 2008-06-26 | Redpoint Bio Corporation | Trpv1 antagonists and uses thereof |
US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
ES2539290T3 (es) | 2008-04-18 | 2015-06-29 | Daewoong Pharmaceutical Co., Ltd. | Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso |
JPWO2009130900A1 (ja) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
EP2309856A4 (en) * | 2008-07-11 | 2012-03-28 | Myrexis Inc | PHARMACEUTICAL COMPOUNDS AS CYTOTOXICA AND ITS APPLICATION |
WO2010029996A1 (ja) * | 2008-09-11 | 2010-03-18 | 協和発酵キリン株式会社 | 医薬組成物 |
US8546388B2 (en) * | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
ES2456275T3 (es) | 2009-02-27 | 2014-04-21 | Ambit Biosciences Corporation | Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
CN103298805A (zh) | 2010-09-01 | 2013-09-11 | 埃姆比特生物科学公司 | 喹唑啉化合物及其使用方法 |
JP5933554B2 (ja) * | 2010-09-01 | 2016-06-15 | アムビト ビオスシエンセス コルポラチオン | 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法 |
JP5916730B2 (ja) | 2010-09-06 | 2016-05-11 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | アミド化合物 |
WO2012044572A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
AU2011346749A1 (en) | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof |
KR20200125765A (ko) | 2011-02-18 | 2020-11-04 | 아사나 바이오사이언시스 엘엘씨 | 아미노인단 화합물 및 통증 치료에서 그것의 용도 |
JP2014522837A (ja) * | 2011-06-29 | 2014-09-08 | 大塚製薬株式会社 | 治療用化合物としてのキナゾリン及び関連の使用方法 |
JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
WO2017031427A1 (en) * | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
US10851123B2 (en) | 2016-02-23 | 2020-12-01 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
CR20180594A (es) | 2016-06-02 | 2019-07-29 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo |
US10239875B2 (en) | 2017-06-16 | 2019-03-26 | King Saud University | Naphthyridinyl hydrazine derivatives as potent peripheral analgesic agents |
CA3077659A1 (en) * | 2017-10-09 | 2019-04-18 | Ramot At Tel-Aviv University Ltd. | Modulators of potassium ion and trpv1 channels and uses thereof |
RU2020117698A (ru) | 2017-12-01 | 2022-01-04 | Эббви Инк. | Агонист глюкокортикоидного рецептора и его иммуноконъюгаты |
CA3123222A1 (en) * | 2018-12-21 | 2020-06-25 | Sorrento Therapeutics, Inc. | Perineural administration of resiniferatoxin for treatment of maladaptive pain |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
MX2023000056A (es) | 2020-07-02 | 2023-04-12 | Incyte Corp | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為jak2 v617f抑制劑之螺環內醯胺 |
CA3237199A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023141661A1 (en) * | 2022-01-24 | 2023-07-27 | Inter-Med, Inc. | Dental material compositions for cleansing and removal of anionic contaminants from substrates & their methods of use |
DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3501696A1 (de) * | 1985-01-19 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
ATE110071T1 (de) * | 1988-01-23 | 1994-09-15 | Kyowa Hakko Kogyo Kk | Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen. |
GB8910722D0 (en) * | 1989-05-10 | 1989-06-28 | Smithkline Beckman Intercredit | Compounds |
GB8928281D0 (en) | 1989-12-14 | 1990-02-21 | Smith Kline French Lab | Compounds |
DE4131029A1 (de) * | 1991-09-18 | 1993-07-29 | Basf Ag | Substituierte pyrido (2,3-d) pyrimidine als antidots |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
TW263498B (es) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
BR9713552A (pt) * | 1996-11-27 | 2000-01-25 | Pfizer | Derivados de pirimidina bicìclicos condensados |
CO4940469A1 (es) * | 1997-03-05 | 2000-07-24 | Sugen Inc | Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol |
US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
WO2001021596A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
CA2386163A1 (en) | 1999-10-01 | 2001-04-12 | Masanori Tobe | Novel quinazoline derivatives |
US6723730B2 (en) | 2000-07-20 | 2004-04-20 | Neurogen Corporation | Capsaicin receptor ligands |
CA2422371C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
PL373484A1 (en) | 2001-12-10 | 2005-09-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US20050154230A1 (en) | 2001-12-26 | 2005-07-14 | Bayer Healthcare Ag | Urea derivatives |
KR20040085151A (ko) * | 2002-01-17 | 2004-10-07 | 뉴로젠 코포레이션 | 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체 |
AU2003241453A1 (en) | 2002-05-17 | 2003-12-02 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
MXPA04011472A (es) * | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
WO2004028440A2 (en) | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Vr1 antagonists for the treatment of urological disorders |
MXPA05006123A (es) * | 2002-12-13 | 2005-09-30 | Neurogen Corp | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. |
AU2003299797A1 (en) * | 2002-12-19 | 2004-07-14 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
EP1678173A2 (en) * | 2003-09-09 | 2006-07-12 | Neurogen Corporation | 4-heterobicyclylamino-substituted quinazolines and analogues thereof as capsaicin-antagonists |
CN1890223A (zh) * | 2003-10-31 | 2007-01-03 | 神经能质公司 | 辣椒素受体促效剂 |
TW200621251A (en) * | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US20080085901A1 (en) * | 2005-01-14 | 2008-04-10 | Neurogen Corporation | Heteroaryl Substituted Quinolin-4-Ylamine Analogues |
-
2003
- 2003-12-12 MX MXPA05006123A patent/MXPA05006123A/es not_active Application Discontinuation
- 2003-12-12 KR KR1020057010845A patent/KR20050084292A/ko not_active Application Discontinuation
- 2003-12-12 JP JP2004560827A patent/JP2006515846A/ja not_active Withdrawn
- 2003-12-12 WO PCT/US2003/039607 patent/WO2004055004A1/en active Application Filing
- 2003-12-12 AU AU2003296984A patent/AU2003296984A1/en not_active Abandoned
- 2003-12-12 US US10/735,607 patent/US20040156869A1/en not_active Abandoned
- 2003-12-12 CN CNA2003801058156A patent/CN1726205A/zh active Pending
- 2003-12-12 JP JP2004560828A patent/JP2006515847A/ja not_active Withdrawn
- 2003-12-12 EP EP03813411A patent/EP1569926A1/en not_active Withdrawn
- 2003-12-12 AU AU2003300898A patent/AU2003300898A1/en not_active Abandoned
- 2003-12-12 TW TW092135120A patent/TW200418480A/zh unknown
- 2003-12-12 WO PCT/US2003/039606 patent/WO2004055003A1/en active Application Filing
- 2003-12-12 EP EP03813410A patent/EP1569925A1/en not_active Withdrawn
- 2003-12-12 US US10/539,031 patent/US7432275B2/en not_active Expired - Fee Related
- 2003-12-12 CA CA002509239A patent/CA2509239A1/en not_active Abandoned
- 2003-12-12 CA CA002509233A patent/CA2509233A1/en not_active Abandoned
- 2003-12-12 AR ARP030104607A patent/AR042461A1/es unknown
- 2003-12-12 BR BR0317168-0A patent/BR0317168A/pt not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000034A patent/PE20040935A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US7432275B2 (en) | 2008-10-07 |
TW200418480A (en) | 2004-10-01 |
AU2003296984A1 (en) | 2004-07-09 |
MXPA05006123A (es) | 2005-09-30 |
WO2004055004A1 (en) | 2004-07-01 |
BR0317168A (pt) | 2005-11-01 |
WO2004055004A8 (en) | 2005-07-21 |
EP1569926A1 (en) | 2005-09-07 |
US20040156869A1 (en) | 2004-08-12 |
EP1569925A1 (en) | 2005-09-07 |
WO2004055003A1 (en) | 2004-07-01 |
KR20050084292A (ko) | 2005-08-26 |
CA2509233A1 (en) | 2004-07-01 |
AR042461A1 (es) | 2005-06-22 |
JP2006515846A (ja) | 2006-06-08 |
JP2006515847A (ja) | 2006-06-08 |
CN1726205A (zh) | 2006-01-25 |
AU2003300898A1 (en) | 2004-07-09 |
CA2509239A1 (en) | 2004-07-01 |
US20060089354A1 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040935A1 (es) | Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina | |
PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
PE20050525A1 (es) | Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1 | |
PE20020720A1 (es) | Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa | |
PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
PE20040720A1 (es) | Derivados de benzodioxol | |
PE20060010A1 (es) | 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C | |
PE20011030A1 (es) | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol | |
NO20032253L (no) | Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer | |
PE20080827A1 (es) | N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2 | |
PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
AR049652A1 (es) | Sales cuaternarias antagonistas del receptor ccr2 | |
AR018917A1 (es) | Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
PE106499A1 (es) | Antagonistas del receptor ccr-3 | |
PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20021094A1 (es) | Derivados de ciclohexano-1,4-diamina sustituidos | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
PE20001303A1 (es) | Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3 | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
AR028817A1 (es) | Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen | |
PE20060632A1 (es) | Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |